Clinical trial · Observational
CTFEA Myeloma Study
Prospective Application of CTFEA for Monitoring Disease Progression in Active Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with Multiple Myeloma are monitored for disease progression and for response to treatment by the treating hematologist or oncologist. Laboratory tests are usually utilized for these purposes. The role of imaging is confined to follow-up the progression of visible bone lesions. We suggest that microscopic bone lesions impair bone structure well before they grow enough to be visible on a CT scan. This impairment of bone strength can probably be captured by application of CT-based finite element analysis to the CT scans that were performed for monitoring of progression of the disease.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Bone Tumor | Bone Neoplasm | CURATED_BROADER | 0.78 |
| Myeloma Multiple | Multiple Myeloma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT-based finite element analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Study group
- description
- All patients referred to the Hematology clinic for diagnosis and treatment of active multiple myeloma will be asked to participate in the study and undergo 3 consecutive low-dose CT scans over a period of 12 months. For non-consenting patients only minimal demographic data will be documented. Eligible consenting patients will sign informed consent.
- interventionNames
- Other: CT-based finite element analysis
Primary outcomes (2)
- measure
- Change in bone strength
- timeFrame
- 12 months
- description
- Identification of changes in bone strength on CT-based FE analysis on three consecutive CT scans that are not apparent to the human eye
- measure
- Quantification of bone strength
- timeFrame
- 12 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 95 Years
Show eligibility criteria text
Inclusion Criteria: * All patients with Active Multiple Myeloma Exclusion Criteria: * Inability to provide informed consent or lack of consent. * Inadequate CT scans
References
Publications (4)
- BACKGROUNDMyeloma: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2018 Oct. Available from http://www.ncbi.nlm.nih.gov/books/NBK553585/ PMID 32045178
- BACKGROUNDSternheim A, Giladi O, Gortzak Y, Drexler M, Salai M, Trabelsi N, Milgrom C, Yosibash Z. Pathological fracture risk assessment in patients with femoral metastases using CT-based finite element methods. A retrospective clinical study. Bone. 2018 May;110:215-220. doi: 10.1016/j.bone.2018.02.011. Epub 2018 Feb 20. PMID 29475110
- BACKGROUNDTerpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018 Jan 12;8(1):7. doi: 10.1038/s41408-017-0037-4. PMID 29330358
- BACKGROUNDOken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available. PMID 7165009